Gudtel-M 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 47.5 mg in an extended-release formulation. Telmisartan, an angiotensin II receptor blocker (ARB), functions by selectively inhibiting the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion, thereby lowering blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to antihypertensive effects and reducing myocardial oxygen demand. The extended-release formulation ensures sustained plasma concentrations, promoting once-daily dosing and improved patient compliance. Gudtel-M 50 is indicated for the management of hypertension, either as monotherapy or in patients inadequately controlled on monotherapy. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure, where beta-blockade is advantageous. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Gudtel-M 50 Tablet ER should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.